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Abstract
Introduction: Non-excitable muscle membrane indicates critical illness myopathy (CIM) during early critical illness. We 
investigated predisposing risk factors for non-excitable muscle membrane at onset of critical illness.
Methods: We performed sequential measurements of muscle membrane excitability after direct muscle stimulation 
(dmCMAP) in 40 intensive care unit (ICU) patients selected upon a simplified acute physiology (SAPS-II) score ≥ 20 on 3 
successive days within 1 week after ICU admission. We then investigated predisposing risk factors, including the 
insulin-like growth factor (IGF)-system, inflammatory, metabolic and hemodynamic parameters, as well as suspected 
medical treatment prior to first occurrence of abnormal dmCMAP. Nonparametric analysis of two-factorial longitudinal 
data and multivariate analysis were used for statistical analysis.
Results: 22 patients showed abnormal muscle membrane excitability during direct muscle stimulation within 7 (5 to 
9.25) days after ICU admission. Significant risk factors for the development of impaired muscle membrane excitability in 
univariate analysis included inflammation, disease severity, catecholamine and sedation requirements, as well as IGF 
binding protein-1 (IGFBP-I), but did not include either adjunctive hydrocortisone treatment in septic shock, nor 
administration of neuromuscular blocking agents or aminoglycosides. In multivariate Cox regression analysis, 
interleukin-6 remained the significant risk factor for the development of impaired muscle membrane excitability (HR 
1.006, 95%-CI (1.002 to 1.011), P = 0.002).
Conclusions: Systemic inflammation during early critical illness was found to be the main risk factor for development 
of CIM during early critical illness. Inflammation-induced impairment of growth-factor mediated insulin sensitivity may 
be involved in the development of CIM.
Introduction
ICU-acquired muscle weakness is a serious complication
of critical illness. It has been recognized as the clinical
manifestation of an ICU-acquired peripheral neuromus-
cular pathology [1] that, with regard to muscle pathology,
is characterized by atrophy of type II muscle fibres and
thick filament myopathy [2].
Diagnosis of critical illness myopathy (CIM) is either
based on clinical proof of muscle weakness after awaken-
ing from analgesia and sedation, measurement of short
duration low amplitude muscle unit potentials, depend-
ing on voluntary muscle contraction, or histological con-
firmation of muscle pathology [2]. As muscle biopsies are
not routinely taken at the onset of critical illness neither
approach is suitable to diagnose CIM at early critical ill-
ness.
Recent studies described measurements of muscle
membrane excitability after direct muscle stimulation as
a valid electrophysiological marker indicating CIM in
critically ill patients [2-5]. As the investigation of muscle
membrane excitability is independent of voluntary mus-
cle contraction, it enables the detection of CIM during
early critical illness when clinical evaluation is generally
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factors for CIM have yielded mixed results [6-8]. Illness
severity [9], duration of immobility [10], systemic inflam-
mation, hyperglycemia [8,11,12], and the use of corticos-
teroids or neuromuscular blocking agents [6] are
disputed risk factors. Recent data suggest a relation
between growth factor-mediated dysregulation of glucose
and protein metabolism due to systemic inflammation
and the development of myopathy [13,14].
Measurement of muscle membrane excitability during
early critical illness offers a unique opportunity to better
understand and investigate early markers and potential
risk factors for non-excitable muscle membrane.
The objective of this study is to investigate predisposing
risk factors for the development of non-excitable muscle
membrane during early critical illness, particularly con-
sidering concentration patterns of the insulin-like growth
factor (IGF)-system prior to first proof of pathologically
reduced muscle membrane excitability.
Materials and methods
This study presents a subanalysis of 40 patients of a
recent prospective observational study [5] that investi-
gated the predictive value of certain electrophysiological
measurements on the development of ICU-acquired
weakness. Validating muscle membrane excitability at the
onset of critical illness turned out to be most valuable for
an early prediction of ICU-acquired weakness in immo-
bile, sedated patients adding important information to
clinical estimation of the patients' motor function upon
emergence from sedation. Mechanically ventilated ICU
patients on an operative ICU who featured simplified
acute physiology (SAPS-II) scores of 20 or higher on
three successive days within one week after ICU admis-
sion were included in the study. Sequential electrophysio-
logical measurements including measurement of muscle
membrane excitability had been performed at study
enrollment and every three days until pathological find-
ings were detected or clinical evaluation of muscle
strength by Medical Research Council (MRC) score was
possible.
Details of electrophysiological measurements are
reported elsewhere [5], in brief we assessed the com-
pound muscle amplitude with concentric needle elec-
trodes after direct stimulation of the muscle. Comparable
with measurement of compound muscle amplitude after
nerve stimulation, this is a quantitative method and the
normal data in critically ill patients are 3 mV or more [3].
Patients with non-excitable muscle membrane after
direct muscle stimulation show reduced amplitudes of
less than 3 mV, whereas patients with an acute neuropa-
thy show normal amplitudes within the muscle after
direct muscle stimulation. Measurement of muscle mem-
brane excitability diagnoses myopathy but cannot exclude
an additional axonal motor neuropathy. Here we focused
on a risk factor analysis of non-excitable muscle mem-
brane from the beginning of critical illness until first
proof of non-excitable muscle membrane. Hence, we
excluded patients being pretreated on other ICUs for
more than 24 hours and only included values of risk fac-
tors of the first eight days of critical illness in the analysis.
The study was approved by our local review board. Writ-
ten informed consent was obtained from legal proxies.
Patients were treated following standard operating pro-
cedures of intensive care incorporating severe sepsis bun-
dles [15]. Systemic inflammation, sepsis or severe sepsis
[see Table E1 in Additional file 1] accompanied by organ
dysfunction [see Table E2 in Additional file 1] was classi-
fied according to consensus conference criteria [16,17].
Inflammatory cytokines (IL-6 and IL-10), IGF-I and its
binding proteins (IGFBP-I, IGFBP-III) were analysed
from blood samples, drawn between days 3 and 7 as well
as between days 8 and 10 after ICU admission.
Hemodynamic parameters and blood glucose levels
were recorded four times daily considering least favorable
values within six-hour intervals. Illness severity, SAPS-II
[18], sepsis-related organ failure assessment (SOFA) [19]
and other clinical data were recorded on a daily basis.
Methods are further described in Additional file 1.
Statistical analysis
Results are expressed as median and 25th/75th percen-
tiles for continuous variables and proportions for qualita-
tive parameters, respectively. We used nonparametric
tests for statistical testing.
Changes in interesting clinical outcomes with respect
to time were analyzed using nonparametric analysis of
longitudinal data in a two-factorial design (1st factor:
compound muscle action potential after direct muscle
stimulation (dmCMAP) normal versus dmCMAP abnor-
mal patients, 2nd factor: repetitions in time), focusing on
values during the first eight days after ICU admission or
within a first interval between days 3 and 7, and a second
interval between days 8 and 10 after ICU admission.
Therefore, we compared all time points simultaneously
on the corresponding response curves [20].
In univariate and subsequently in multivariate Cox'
proportional hazard regressions (stepwise backward pro-
cedure), we tested risk factors impairing muscle mem-
brane excitability (as a dependent variable). For all
parameters we included values from days of first IL-6
measurements in the analysis. Hazard ratios (HR) with
their 95% confidence intervals (CI) and the correspond-
ing P values were calculated for each risk factor. P values
less than 0.05 (two-sided) were considered as statistically
significant.
We evaluated the diagnostic test performance of IL-6
and SOFA to indicate the development of myopathy by
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abnormal dmCMAP amplitude less than 3 mV as electro-
physiological parameter for diagnosis of myopathy and
IL-6 as well as SOFA as test variables. We combined the
diagnostic tests regarding sensitivity and specificity of
SOFA and IL-6 to indicate myopathy with the help of the
known 'believe-the-positive' rule.
All tests should be understood as constituting explor-
atory data analysis, such that no adjustments for multiple
testing have been made. We used SPSS, Version 14 (SPSS,
Inc., Chicago, IL, USA), and SAS, Version 9.1 (SAS Insti-
tute, Inc., Cary, NC, USA).
Results
Patient characteristics
Forty patients at the onset of critical illness were enrolled
in the study. Twenty-two patients developed abnormal
muscle membrane excitability in terms of reduced com-
pound muscle action potential after direct muscle stimu-
lation (dmCMAP abnormal) within 7 (5 to 9.25) days
after admission to ICU as reported earlier [5]. Eighteen
patients showed normal muscle membrane excitability
(dmCMAP normal). Patients with abnormal dmCMAP
revealed significant paresis (MRC 2.6 (1.84 to 3.27)) after
emergence from sedation compared with patients with
normal dmCMAP (MRC 4.1 (4 to 4.84); (P < 0.0001). ICU
length of stay was significantly prolonged in dmCMAP
abnormal patients (26 (18 to 38) days) compared with
dmCMAP normal patients (13 (8 to 18) days; P < 0.0001).
Patients' characteristics upon admission and within the
first eight days after ICU admission are shown in Table 1.
Risk factors of critical illness myopathy in dmCMAP
normal and dmCMAP abnormal patients within the first
week after ICU admission.
Within the first eight days after ICU admission,
patients with abnormal dmCMAP had significantly more
days with systemic inflammatory response syndrome,
severe sepsis, and dysfunction of two or more organs
compared with patients with normal dmCMAP (Table 1
and Figure 1).
Moreover, patients with abnormal dmCMAP received
significantly higher doses of norepinephrine within the
first week after ICU admission (Figure 2). Hemodynamic
stability in terms of circulatory shock was significantly
impaired within the first eight days compared with dmC-
MAP normal patients (Figure 2). There was no difference
regarding frequency and cumulative dosage of adjunctive
hydrocortisone therapy within the first week after ICU
admission between the two groups (Table 1).
DmCMAP abnormal patients received significantly
higher doses of analgesics and sedation and more neuro-
muscular blocking agents; however, the cumulative dos-
age of neuromuscular blocking agents was low within
both groups (Table 1).
IL-6 plasma levels were significantly higher within the
first week (day 5 (3 to 7)) in patients with abnormal dmC-
MAP. In the second week (day 8 (6 to 10.25)), IL-6
decreased in both groups but remained significantly
higher in dmCMAP abnormal patients. There was no dif-
ference between the two groups regarding IL-10 plasma
levels (Figure 3).
Daily blood glucose levels (Figure 4), total carbohydrate
intake, insulin requirement (Table 1), and the insulin per
kcal carbohydrate intake (Figure 4) were not significantly
different between the two groups within the first week.
Patients with abnormal dmCMAP had a significantly
higher plasma osmolarity and sodium plasma levels dur-
ing the first eight days after ICU admission than dmC-
MAP normal patients (Figure 5).
IGF-I was reduced in dmCMAP abnormal patients at
both test intervals (87.2 ng/ml (65.9 to 119.5) versus 104.5
ng/ml (74.4 to 136.9) and 76.1 ng/ml (55.1 to 119.5) ver-
sus 87.2 ng/ml (65.8 to 122)), but differences did not
reach statistical significance. Plasma levels of IGFBP-III
were not different between both groups whereas IGFBP-I
as a marker reflecting impaired insulin sensitivity was sig-
nificantly higher in dmCMAP abnormal patients at both
test intervals (Figure 6).
Cox' regressions analysis
Separate (univariate) Cox regression analyses for risk fac-
tors impairing muscle membrane excitability are shown
in Table 2. Analyses included values from day of first IL-6
measurements.
In univariate analysis severity of illness, sepsis-related
organ dysfunction, inflammation, catecholamine require-
ments, sedation requirements and an impaired insulin
sensitivity turned out as significant risk factors for the
development of impaired muscle membrane excitability
within the early course of critical illness. An increased
osmolarity, adjunctive hydrocortisone treatment in septic
shock, administration of neuromuscular blocking agents
and aminoglycosides were not significantly correlated
with the development of impaired muscle membrane
excitability.
In the backward selection of multivariate Cox regres-
sion analysis (Figure 7) the extent of inflammation as
reflected by IL-6 plasma levels and the fentanyl dosage
remained as independent risk factors for the develop-
ment of impaired muscle membrane excitability.
Sensitivity and specificity
Sensitivity and specificity of SOFA score to predict
abnormal membrane excitability was highest on day 4 at a
cut-off value of 10 (sensitivity = 65% and specificity =
93.8%). The cut-off value for IL-6 predicting abnormal
membrane excitability was observed at 230 pg/ml, featur-
ing sensitivity of 71.4% and specificity of 93.3%. Accord-
ing to the 'believe the positive' rule applied in a combined
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Table 1: Patients' characteristics within the first week after ICU admission in patients without and with critical illness myopathy
dmCMAP Normal Abnormal P
Number of patients Total 40 18 22
Age Years 42 (24.3/58.5) 58 (42.5/68.3) 0.06b
Gender male/female 12/6 15/7 1a
Survival survivor/non-survivor 17/1 14/8 0.03a
BMI kg/m2 24.8 (20.5/26.6) 25.4 (23.3/29.7) 0.19b
Reason of ICU admission Multiple trauma. total n (%) 11 (61.1) 10 (45.5) 0.25a
Pneumonia. total n (%) 3 (16.7) 7 (31.8)
Abdominal cancer. total n (%) 2 (11.1) 5 (22.7)
Others. total n (%) 2 (11.1) 0
ICU admission SAPS-II 31.5 (23.8/42) 41.0 (36.3/48.3) 0.02b
SOFA 8.0 (5.8/10.3) 10.0 (7/12.5) 0.07b
White blood cell count (1/nl) 9.6 (8.4/12.6) 8.8 (6.5/11.6) 0.26b
Plasma CRP (mg/dl) 17.1 (11.03/23.9) 17.2 (10.8/26.1) 0.72b
Plasma urea (mg/dl) 33 (21/53.8) 55.5 (33.8/102.5) 0.001b
Plasma creatinine (mg/dl) 1.02 (0.73/1.24) 1.5 (0.92/2.6) 0.001b
PaO2/FiO2 205.5 (183/247.5) 177.4 (91/256) 0.4b
Plasma lactate (mmol/l) 2.15 (1.5/2.5) 3.35 (2.02/6.02) 0.02b
Plasma pH 7.36 (7.3/7.47) 7.28 (7.2/7.48) 0.08b
Inflammation day 1-8
(cum. %)
SIRS 75.0 (52.2/100) 87.5 (71.9/100) 0.18a
Severe sepsis 25.0 (0/62.5) 68.8 (9.4/87.5) 0.075a
Septic shock 12.5 (0/50) 56.2 (0/87.5) 0.022a
Organ dysfunction day 1-8
(cum. %)
Coagulation 18.75 (0/77.7) 62.5 (9.4/100) 0.26a
Lung 33.3 (18.75/75) 68.75 (25/100) 0.15a
Renal 0 (0/0) 0 (0/56.3) 0.21a
Liver 0 (0/31.3) 25 (0/50) 0.12a
Metabolic acidosis 0 (0/18.75) 12.5 (0/50) 0.08a
GCS < 13 0 (0/7.14) 6.25 (0/75) 0.2a
Organ dysfunction > 2 0 (0/0) 37.5 (0/62.5) 0.003a
Drugs days 1 to 8
(% pat; cum dosage per pat.)
Norepinephrine (mg) 61.1; 8.9 (2.7/35.6) 91; 60.1 (27.5/84.1) 0.05b; 
0.003b
Dobutamine (mg) 27.8; 581 (259/951) 54.5; 1975 (958/4399) 0.12b; 
0.019b
NMBA (mg) 55.6; 10 (9.3/20) 63.6; 27.5 (17.5/45) 0.75b; 
0.016b
Aminoglycosides (mg) 16.7; 1440 (1260/
1440)
27.3; 420 (320/620) 0.48b; 
0.024b
Hydrocortisone (mg) 16.7; 719 (501/719) 36.4; 836 (598/963) 0.29b; 1.0b
Carbohydrates (kcal/kg) 94.4; 64.7 (29.2/103.2) 95.5; 59.7 (50.6/83.4) 1.0b; 0.95b
Insulin (IU) 100; 237.8 (165/370) 95.5; 331.2 (155/590) 1.0b; 0.2b
Fentanyl (mg) 94.4; 18.4 (7/26.5) 95.5; 36 (19.8/69.5) 1.0b; 
0.006b
Midazolam (mg) 77.8; 726 (318/1292) 90.9; 1702 (810/3593) 0.38b; 
0.05b
Myopathy according to direct muscle stimulated compound muscle action potential (dmCMAP) at onset of critical illness, normal (≥3 mV) and 
abnormal (< 3 mV); parameters are calculated upon ICU admission or within eight days after ICU admission.
BMI, body mass index; CRP, C-reactive protein; GCS, Glasgow Coma Scale; NMBA, neuromuscular blocking agent; PaO2/FiO2, index of arterial 
oxygenation efficiency corresponding to ratio of partial pressure of arterial O2 to the fraction of inspired O2; SAPS-II, simplified acute physiology 
score; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment score; (cum. %), cumulative fractions of 
presented parameters calculated by sum of days fulfilling criteria of a particular parameter divided by total days of ICU presence within the first 
eight days after ICU admission; (% patients), proportion of patients; (cum. dosage), cumulative drug dose within the first eight days after ICU 
admission. Qualitative data are given as proportions (%). Continuous data and cumulative fractions are given as median and 25%/75% percentile; 
aFisher's exact test, bMann-Whitney U rank test.
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more at day 4 after ICU admission and/or IL-6 plasma
levels of 230 pg/ml or more, we observed a sensitivity of
85.7% and a specificity of 86.7% of this combination for
predicting development of abnormal dmCMAP.
Discussion
In this observational study we investigated predisposing
risk factors leading to non-excitable muscle membrane
indicating CIM during early critical illness. The main
finding was a significant relation between muscle mem-
brane inexcitability, disease severity and IL-6 plasma lev-
els.
In the absence of a reliable clinical parameter identify-
ing patients at risk of developing CIM during early criti-
cal illness, when motor function is not assessable due to
analgesia and sedation, current data on risk factors lead-
ing to CIM are derived mostly from prospective cohort
studies relating data from ICU admission with patients'
motor function once assessable [6]. One excellent study
investigating risk factors for combined critical illness
neuromyopathy [9] during early critical illness showed
that illness severity, determined through acute physiology
and chronic health evaluation (APACHE) III scores, pre-
dicted the later development of critical illness neuromyo-
pathy. In our study, sequential measurements of muscle
membrane excitability offers the opportunity to focus on
CIM and to determine the time frame in which CIM orig-
inates during early critical illness, thereby improving
stratification of predisposing risk factors for CIM.
Univariate analysis indicated illness severity, IL-6,
hemodynamic impairment, decreased insulin sensitivity
as well as analgesia and sedation as predisposing risk fac-
tors. However, only IL-6 and dosage of analgesia emerged
as independent risk factors from multivariate analysis.
Interestingly, we did not observe any significant relation
between development of non-excitable muscle mem-
brane and application of low-dose hydrocortisone, amin-
oglycosides or neuromuscular blocking agents, which
have frequently been incriminated as being involved in
the development of CIM.
Large prospective randomized studies have shown that
glycemic control is associated with the development of
neuromuscular dysfunction [11,12]. In our study, we did
not observe a difference in blood glucose levels between
dmCMAP normal and abnormal patients because we
aimed for glycemic control below 150 mg/dl in all of our
patients. However, despite comparable blood glucose lev-
els between the groups, IGFBP-1 was significantly higher
in abnormal dmCMAP patients. In agreement with other
Figure 1 Critical illness myopathy and disease severity scores. Normal (≥3 mV) and abnormal (< 3 mV) direct muscle stimulation compound mus-
cle action potentials (dmCMAP), (a) simplified acute physiology score-II (SAPS-II) and (B) sequential organ failure assessment (SOFA) score on the first 
eight days after ICU admission. Patients with impaired muscle membrane excitability had significantly higher SAPS-II and SOFA scores during the first 
eight days after ICU admission. Nonparametric analysis of longitudinal data in a two-factorial design (1st factor: dmCMAP normal versus dmCMAP 
abnormal, 2nd factor: repetitions in time. The statistical analysis was the same for Figures 1 to 6, either focusing on values from the first eight days after 
ICU admission (Figures 1, 2, 4 and 5) or referring to a first and second interval between days 3 and 7 after ICU admission and between days 8 and 10 
after ICU admission, respectively (Figures 3 and 6).
(a)            (b) 
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Figure 2 Critical illness myopathy and hemodynamic variables. Normal (≥3 mV) and abnormal (< 3 mV) direct muscle stimulation compound 
muscle action potentials (dmCMAP), (a) mean shock index and (b) daily norepinephrine dosage on the first eight days after ICU admission. Patients 
with impaired muscle membrane excitability had significantly higher shock indices and required significantly higher daily norepinephrine dosages 
during the first eight days after ICU admission.
(a)          (b) 
Figure 3 Critical illness myopathy and systemic inflammation. Normal (≥3 mV) and abnormal (< 3 mV) direct muscle stimulation compound mus-
cle action potentials (dmCMAP), (a) IL-6 plasma levels, (b) IL-10 plasma levels at median day (25th/75th percentile) 5 (3 to 7) and median day 8 (6 to 
10,25). Patients with impaired muscle membrane excitability had significantly higher IL-6 plasma levels but no significant differences of IL-10 plasma 
levels at both measurement intervals.
(a)        (b) 
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parameter indicative of impaired insulin sensitivity.
Hence, our data suggest that significantly impaired insu-
lin sensitivity during early critical illness was related to
development of abnormal muscle membrane excitability.
In parallel, dmCMAP abnormal patients revealed a sig-
nificant hyperosmotic state within the first days of critical
illness. Hyperosmolality is related to illness severity [23]
and has been described as a risk factor for critical illness
neuropathy [24]. It is worth noting that the study by Gar-
nacho-Montero and colleagues [24] did not differentiate
between myopathy and neuropathy. In our study, hyper-
osmolality during the first days after ICU admission was
significantly related to electrophysiological-proven mus-
cle pathology. It can be speculated that this hyperosmotic
state may have led to osmotic stress-induced reduction of
cellular insulin sensitivity in our patients, which has been
shown in adipocytes under experimental conditions [25].
However, alteration of insulin sensitivity and plasma
osmolality are most likely related to systemic inflamma-
tion in our study. Our data are in agreement with the gen-
eral perception that systemic inflammation and sepsis-
related organ dysfunction are major triggers for the
development of CIM [6,8,9,26]. Earlier experimental data
inducing inflammation in rats by intravenous inoculation
of endotoxin showed that IL-6 increased muscle fatigue
[27] and decreased muscle contractility of the diaphragm
[28]. Interestingly, recent clinical data indicate a relation
between IL-6 and reduced muscle strength in elderly peo-
ple [29]. Our data reveal a possible role of IL-6 in the
development of non-excitable muscle membrane during
early critical illness finally leading to muscle weakness.
IL-6 seems to be an important mediator leading to
muscle protein breakdown [30]. One mechanism may lie
in the inhibition of growth factor-mediated (e.g. IGF-I)
intracellular signaling by IL-6 [13,31]. IGF-I plays a cen-
tral role in glucose uptake and protein synthesis, and was
shown to be downregulated in inflammation and sepsis
[13]. Impairment of IGF-I may be due to inflammation-
induced upregulation of high-affinity IGFBP-1 which
prevents IGF-I receptor binding [32]. In vitro [33] and
later in vivo [14], it has been shown that an increase of
IGFBP-1 reduced the IGF-I-mediated glucose uptake and
reduced protein synthesis in skeletal muscle within an
experimental setting. In line with this, our data suggest
that impaired growth factor-mediated intracellular sig-
naling due to systemic inflammation may be involved in
the development of CIM.
Corticosteroids are controversially discussed as aggra-
vating factors of CIM [6,7,9,34]. It is well established that
high-dose application of corticosteroids, for example in
patients with chronic obstructive pulmonary disease,
results in selective loss of thick myosin filaments in skele-
Figure 4 Critical illness myopathy and glycemic control. Normal (≥3 mV) and abnormal (< 3 mV) direct muscle stimulation compound muscle 
action potentials (dmCMAP), (a) mean blood glucose levels and (b) insulin in relation to daily carbohydrate intake on the first eight days after ICU 
admission. Mean blood glucose levels and insulin in relation to daily carbohydrate intake did not differ significantly in patients with impaired muscle 
membrane excitability compared with patients with normal membrane excitability.
(a)        (b) 
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thy [36].
Nevertheless, these reports refer to steroid myopathy as
a result of high-dose steroid application. A link between
'low-dose hydrocortisone' treatment as adjunctive ther-
apy during septic shock and development of CIM has
been postulated [15], but never proven. Several data indi-
cate that moderate doses of steroids do not prolong
mechanical ventilation due to muscle weakness but are
related to significantly more ventilator-free days and ear-
Figure 5 Critical illness myopathy and plasma homeostasis. Normal (≥3 mV) and abnormal (< 3 mV) direct muscle stimulation compound muscle 
action potentials (dmCMAP), (a) plasma sodium, (b) plasma osmolarity, (c) plasma pH and (d) plasma urea (multiply by factor 0.46 for blood urea ni-
trogen (BUN) conversion) over the first eight days after ICU admission. Patients with impaired muscle membrane excitability had significantly higher 
plasma sodium, plasma osmolarity, plasma pH and plasma urea during the first eight days after ICU admission.
(a)                  (b) 
          (c)         (d) 
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Figure 6 Critical illness myopathy and insulin sensitivity. Normal (≥3 mV) and abnormal (< 3 mV) direct muscle stimulation compound muscle 
action potentials (dmCMAP), (a) insulin-like growth factor binding protein (IGFBP)-1 plasma levels, (b) IGFBP-3 plasma levels at median day (25th/75th 
percentile) 5 (3 to 7) and median day 8 (6 to 10,25). Patients with impaired muscle membrane excitability had significantly higher IGFBP-1 plasma levels 
but no significant differences of IGFBP-3 plasma levels at both measurement intervals.
(a)                (b) 
Table 2: Risk factors leading to impaired muscle membrane excitability
Cox' regression with time dependent covariates Hazard ratio 95% CI P
LL UL
Univariate
SOFA 1.175 1.042 1.324 0.008
SAPS-II 1.019 0.998 1.04 0.018
Norepinephrine 1.006 1.002 1.011 0.004
Dobutamine 1.000 1.000 1.001 0.004
Midazolam 1.001 1.000 1.001 0.012
Fentanyl 1.026 1.003 1.048 0.024
HC in septic shock 1.001 0.999 1.003 0.310
NMBA (Cisatracurium) 1.027 0.934 1.128 0.58
Aminoglycoside (Tobramycin) 0.99 0.99 1.007 0.791
Osmolarity 1.012 0.992 1.032 0.258
IGFPB-1 1.012 1.004 1.020 0.003
C-reactive protein 1.058 0.994 1.125 0.075
IL-6 1.006 1.003 1.009 < 0.0001
Univariate Cox' proportional hazard regression with time dependent covariates for variables considered risk factors impairing muscle membrane 
excitability (as dependent variable) are shown. For the particular parameter repeated measures of daily cumulative dosages, daily plasma levels 
or daily score values until first proof of reduced muscle membrane excitability in compound muscle action potential after direct muscle 
stimulation (dmCMAP) abnormal patients or until ICU discharge in dmCMAP normal patients were included in the analysis. HC, adjunctive 
hydrocortisone treatment in septic shock; IGFBP-1, insulin-like growth factor-binding protein-1; IL-6, interleukin-6; NMBA, neuromuscular 
blocking agent; SOFA, sequential organ failure assessment score; SAPS-II, simplified acute physiology score. Hazard ratios (HR) with LL (lower 
limit) and UL (upper limit), 95% confidence intervals (95% CI) and P values for each variable.
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study we did not observe an association between low-
dose hydrocortisone application and development of
paresis [5,34]. In this study we were able to show that
low-dose hydrocortisone application does not provoke
impaired muscle membrane excitability, suggesting that
steroid involvement in CIM development is dose depen-
dent [8].
Furthermore, dosage of analgesics and sedatives was
significantly associated with the development of non-
excitable muscle membrane. Interpreting higher doses of
analgesics and sedatives as higher degrees of immobiliza-
tion, this finding is in line with recent studies describing
that immobilization aggravated neuromuscular weak-
ness in an experimental setting [38] and that early physi-
cal mobilization resulted in a better clinical outcome of
motor function [10].
For clinicians it is difficult to estimate patients at risk
for the development of CIM. The APACHE-III score has
been cited as being able to identify patients at risk for
critical illness neuromyopathy [9]. In our study we used
the SOFA score because it is widely accepted in the ICU
setting, and has been validated to monitor organ dysfunc-
tion-related to sepsis [19]. Our results indicate that a
SOFA score of 10 or above and/or IL-6 plasma levels of
230 pg/ml or more at the onset of critical illness disclose
high-risk patients for the development of non-excitable
muscle membrane.
The following limitations of this study need to be
addressed. Although we observed a statistically signifi-
cant effect for IL-6 as a main risk factor for non-excitable
muscle membrane, it has to be stressed that the overall
effect was small, which may be due to small sample size. It
also needs to be mentioned that blood samples were col-
Figure 7 Multivariate Cox' proportional hazard regression after backward selection for variables, that were considered as risk factors im-
pairing muscle membrane excitability (as dependent variable). For the particular parameter values from the day of first blood sampling for IL-6 
were included in the analysis. Hazard ratios (HR) with (95% confidence intervals (CI) and P values for each variable. HC, adjunctive hydrocortisone treat-
ment in septic shock; IGFBP, insulin-like growth factor-binding protein; IL-6, interleukin-6; SOFA, sequential organ failure assessment score.
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Page 11 of 12lected at two different time points only and that the
course of inflammatory parameters was not followed
daily. However, this was designed as a pilot study for
hypothesis generation. The clinical significance has to be
addressed in further studies.
Conclusions
Systemic inflammation during early critical illness turned
out to be the main risk factor for the development of non-
excitable muscle membrane indicating CIM. It may be
hypothesized that inflammation-induced impairment of
growth factor-mediated intracellular signaling is involved
in the pathophysiology of CIM. Furthermore, adjunctive
treatment with low-dose hydrocortisone during septic
shock was not associated with development of CIM.
Key messages
• Non-excitable muscle membrane indicates CIM 
during early critical illness.
• Inflammation, disease severity, decreased insulin 
sensitivity, catecholamine and sedation requirement 
turned out to be significantly related to the develop-
ment of impaired muscle membrane excitability.
• IL-6 and dosage of analgesia emerged as indepen-
dent risk factors from multivariate analysis.
• Inflammation-induced impairment of growth-fac-
tor-mediated insulin sensitivity may be involved in 
the development of CIM.
• In contrast to prior assumptions we could not 
observe any significant relation between development 
of CIM and application of low-dose hydrocortisone in 
septic shock.
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